Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.oret.2018.06.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Protracted Intralenticular Implant of Sustained-Release Dexamethasone Implant (Ozurdex).
Klin Monbl Augenheilkd
April 2024
Vitreoretinal, University of Lausanne, Jules-Gonin Eye Hospital, Lausanne, Switzerland.
Accidental intralenticular injection of a dexamethasone implant in an adult male.
Can J Ophthalmol
October 2023
Saskatchewan Health Authority, Regina, SK.
Effect of intralenticular dexamethasone implant: A case report.
Eur J Ophthalmol
January 2024
Department of Ophthalmology, University "Magna Græcia", Catanzaro, Italy.
Introduction: Intravitreal dexamethasone (DEX) implant is indicated for the treatment of macular oedema due to diabetic retinopathy, retinal vein occlusion and uveitis. The most common complications are cataract and elevated intraocular pressure (IOP). Accidental injection of DEX implant into the lens is a rare complication and only few papers presented it.
View Article and Find Full Text PDFIntralenticular Ozurdex injection in an eye with thicker lens and the therapeutic effect maintained for 15 months.
Heliyon
December 2022
Department of Ophthalmology, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Introduction: To report a case of accidental intralenticular Ozurdex injection in an eye with thicker lens. During the follow-up period of 15 months, the therapeutic effect of intralenticular Ozurdex was maintained.
Case Description: Ozurdex was accidently injected into the lens of an eye with uveitis, and the lens thickness was measured to be 5.
Surgical removal of inadvertent intralenticular sustained-release dexamethasone implant (ozurdex) and implant one-piece posterior capsule intraocular lens.
Saudi J Ophthalmol
December 2020
Dhahran Eye Specialist Hospital, Dhahran, Saudi Arabia.
To report the therapeutic efficacy and results of an accidentally injected intralenticular sustained-release dexamethasone implant (Ozurdex) in a patient with macular edema secondary to diabetic macular edema. Dexamethasone intravitreal implant is an approved formulation in the management of macular edema. The most common adversarial effects are an elevation of intraocular pressure (IOP) and cataract, but the unintentional injection of the dexamethasone implant into the lens is a particularly rare event.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!